drugset
drugset / Trial / NCT01720901

Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy

NCT01720901 ↗

Phase 4 Suspended 20 enrolled Betta Pharmaceuticals Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of increased dose of icotinib in advanced NSCLC patients who progressed after gefitinib therapy.

Timeline

Start
2013-02
Primary completion
2015-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Icotinib Small molecule 250 mg —

Indications

non-small cell lung carcinoma